Format

Send to

Choose Destination
Am J Obstet Gynecol. 2003 Nov;189(5):1297-300.

Treatment of vaginitis caused by Candida glabrata: use of topical boric acid and flucytosine.

Author information

1
Division of Infectious Diseases, Wayne State University School of Medicine, Harper Hospital, 3990 John R, Detroit, MI 48201, USA. jsobel@intmed.wayne.edu

Abstract

OBJECTIVE:

The purpose of this study was to review the treatment outcome and safety of topical therapy with boric acid and flucytosine in women with Candida glabrata vaginitis.

STUDY DESIGN:

This was a retrospective review of case records of 141 women with positive vaginal cultures of C glabrata at two sites, Wayne State University School of Medicine and Ben Gurion University.

RESULTS:

The boric acid regimen, 600 mg daily for 2 to 3 weeks, achieved clinical and mycologic success in 47 of 73 symptomatic women (64%) in Detroit and 27 of 38 symptomatic women (71%) in Beer Sheba. No advantage was observed in extending therapy for 14 to 21 days. Topical flucytosine cream administered nightly for 14 days was associated with a successful outcome in 27 of 30 of women (90%) whose condition had failed to respond to boric acid and azole therapy. Local side effects were uncommon with both regimens.

CONCLUSIONS:

Topical boric acid and flucytosine are useful additions to therapy for women with azole-refractory C glabrata vaginitis.

PMID:
14634557
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center